Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Abbott Laboratories : CONFIRMS CAPACITY TO SUPPORT EXPANDED USE OF HEARTMATE 3 HEART PUMP PARK

06/04/2021 | 07:33am EDT

Abbott (NYSE: ABT) announced the company has capacity and supply to effectively support the growing demand for mechanical circulatory support (MCS) devices for the effective treatment of advanced heart failure following Medtronic's decision to stop the global distribution and sale of the Medtronic HeartWare ventricular assist device (HVAD). Abbott is also supporting training and education programs for additional physicians who will now be offering Abbott's HeartMate 3 heart pumps to their patients.

For patients with advanced heart failure who are either awaiting a heart transplant or not eligible for transplantation, left ventricular assist devices (LVADs) remain a critical option that can extend survival and restore quality of life. To support patients and their physicians, Abbott's HeartMate 3 heart pump is available to physicians and patients around the world in markets where the technology has been approved for use.

'For years we have seen truly life-saving results in patients treated with mechanical circulatory support devices. Ensuring continued access to these devices is critical for patients,' said Mike Pederson, senior vice president of Abbott's electrophysiology and heart failure business. 'We are working to ensure that physicians have the support and training they need as they further adopt HeartMate 3 to improve outcomes for their advanced heart failure patients.'

Abbott's HeartMate 3 heart pump is a small, implantable mechanical circulatory support device for advanced heart failure patients requiring either short- or long-term support who are awaiting a heart transplant or who are not candidates for heart transplantation. The pump has a proven mortality benefit and strong safety profile that has led to longer, improved lives for thousands of advanced heart failure patients around the world. In a recent study of risk adjusted and propensity matched patients supported with the HeartMate 3 published in the Annals of Thoracic Surgery, actuarial survival rates were found to be 87% at one year and 84% at two years.

In addition to extending the lives of patients with advanced heart failure, Abbott's HeartMate 3 heart pump can significantly improve quality of life and reduce adverse events. In addition, HeartMate 3 is approved for pediatric use. To date, nearly 18,000 patients around the world have been supported by the HeartMate 3 heart pump.

For more information on Abbott's market-leading heart failure portfolio, please visit: https://www.cardiovascular.abbott.

About Abbott:

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.

Contact:

Abbott Media

Justin Paquette

T: (612) 219-0375

Abbott Financial

Mike Comilla

T: (224) 668-1872

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about ABBOTT LABORATORIES
08/03INSIDER TRENDS : Insider at Abbott Laboratories Makes Shares Sale for Tax Slowin..
MT
08/03ABBOTT LABORATORIES : Secures FDA Clearance for Ultreon Software-Powered Optical..
MT
08/03ABBOTT : Receives FDA Clearance for its Imaging Technology Using Artificial Inte..
PR
08/03Abbott Gets FDA Approval for AI-Powered Imaging Tech
DJ
08/02Abbott Labs to pay $160 million over kickbacks, false diabetes claims to Medi..
RE
08/02Abbott's FreeStyle« Libre 2 iOS App Cleared in U.S., Providing a Seamless Dig..
CI
07/30ABBOTT LABORATORIES : - half of americans living with diabetes may be consuming ..
AQ
07/29NEW STUDY : Half of Americans Living with Diabetes May be Consuming Less Than th..
PR
07/27Global markets live: LVMH, Michelin, Tesla, Amazon, Activision...
07/23ABBOTT LABORATORIES : Jefferies & Co Adjusts Abbott Laboratories PT to $135 From..
MT
More news
Financials (USD)
Sales 2021 39 766 M - -
Net income 2021 5 967 M - -
Net Debt 2021 8 719 M - -
P/E ratio 2021 36,4x
Yield 2021 1,40%
Capitalization 217 B 217 B -
EV / Sales 2021 5,68x
EV / Sales 2022 5,63x
Nbr of Employees 109 000
Free-Float 89,0%
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | MarketScreener
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 122,12 $
Average target price 128,81 $
Spread / Average Target 5,48%
EPS Revisions
Managers and Directors
Robert B. Ford President, CEO, Chief Operating Officer & Director
Robert Emmett Funck Chief Financial Officer & Executive Vice President
Miles D. White Executive Chairman
Sabina Ewing Chief Investment Officer, VP-Business & Technology
Roxanne Schuh Austin Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ABBOTT LABORATORIES10.44%216 985
MEDTRONIC PLC12.05%176 670
BECTON, DICKINSON AND COMPANY2.22%74 383
HOYA CORPORATION15.49%55 510
ALIGN TECHNOLOGY, INC.31.24%55 502
SARTORIUS STEDIM BIOTECH65.93%52 806